Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H25N3O3S |
Molecular Weight | 459.56 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](NC(=O)C1=C(NS(C)(=O)=O)C(=NC2=CC=CC=C12)C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=QYTBBBAHNIWFOD-NRFANRHFSA-N
InChI=1S/C26H25N3O3S/c1-3-21(18-12-6-4-7-13-18)28-26(30)23-20-16-10-11-17-22(20)27-24(19-14-8-5-9-15-19)25(23)29-33(2,31)32/h4-17,21,29H,3H2,1-2H3,(H,28,30)/t21-/m0/s1
Pavinetant, also known as MLE-4901, AZD-4901, AZD-2624, is a small molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist developed for schizophrenia, hot flashes, and Polycystic ovary syndrome. The development for schizophrenia was discontinued due to lack of effectiveness. Phase II trials for polycystic ovary syndrome and for hot flashes showed the clinical risks exceeded benefits, in addition, abnormal liver function was observed, and that is why these studies were also discontinued.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4429 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27298001 |
1.6 nM [IC50] |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00686998
AZD2624 40 mg
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C166698
Created by
admin on Sat Dec 16 01:46:50 GMT 2023 , Edited by admin on Sat Dec 16 01:46:50 GMT 2023
|
PRIMARY | |||
|
3U471ZVC5K
Created by
admin on Sat Dec 16 01:46:50 GMT 2023 , Edited by admin on Sat Dec 16 01:46:50 GMT 2023
|
PRIMARY | |||
|
23649245
Created by
admin on Sat Dec 16 01:46:50 GMT 2023 , Edited by admin on Sat Dec 16 01:46:50 GMT 2023
|
PRIMARY | |||
|
DE-149
Created by
admin on Sat Dec 16 01:46:50 GMT 2023 , Edited by admin on Sat Dec 16 01:46:50 GMT 2023
|
PRIMARY | |||
|
10773
Created by
admin on Sat Dec 16 01:46:50 GMT 2023 , Edited by admin on Sat Dec 16 01:46:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545233
Created by
admin on Sat Dec 16 01:46:50 GMT 2023 , Edited by admin on Sat Dec 16 01:46:50 GMT 2023
|
PRIMARY | |||
|
100000181125
Created by
admin on Sat Dec 16 01:46:50 GMT 2023 , Edited by admin on Sat Dec 16 01:46:50 GMT 2023
|
PRIMARY | |||
|
DTXSID10916204
Created by
admin on Sat Dec 16 01:46:50 GMT 2023 , Edited by admin on Sat Dec 16 01:46:50 GMT 2023
|
PRIMARY | |||
|
DB11692
Created by
admin on Sat Dec 16 01:46:50 GMT 2023 , Edited by admin on Sat Dec 16 01:46:50 GMT 2023
|
PRIMARY | |||
|
941690-55-7
Created by
admin on Sat Dec 16 01:46:50 GMT 2023 , Edited by admin on Sat Dec 16 01:46:50 GMT 2023
|
PRIMARY | |||
|
AZD-2624
Created by
admin on Sat Dec 16 01:46:50 GMT 2023 , Edited by admin on Sat Dec 16 01:46:50 GMT 2023
|
PRIMARY | |||
|
140478
Created by
admin on Sat Dec 16 01:46:50 GMT 2023 , Edited by admin on Sat Dec 16 01:46:50 GMT 2023
|
PRIMARY |
ACTIVE MOIETY